Gain Therapeutics
GANX
16 hedge funds and large institutions have $4.75M invested in Gain Therapeutics in 2022 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 4 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
0.89% more ownership
Funds ownership: 8.89% → 9.78% (+0.89%)
16% less funds holding
Funds holding: 19 → 16 (-3)
17% less capital invested
Capital invested by funds: $5.71M → $4.75M (-$959K)
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TI
Telemetry Investments
New York
|
+$372K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$165K |
| 3 |
CM
CM Management
Gulf Breeze,
Florida
|
+$146K |
| 4 |
Jane Street
New York
|
+$49K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$23.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$106K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$103K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$70K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$41.8K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$26.8K |
GANX Hedge Fund Activity: Q1 2022 in Review
16 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Gain Therapeutics (GANX) for Q1 2022, worth a combined $4.75M — down 17% from $5.71M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of GANX and 1 opened new positions — a net loss of 3 holders — while 5 trimmed existing stakes and 6 added.
The largest buyer was Telemetry Investments, adding an estimated $372K. The largest seller was Two Sigma Investments, exiting entirely with an estimated $106K sold.
- 16 institutional investors held Gain Therapeutics (GANX) as of Q1 2022, down from 19 in Q4 2021.
- Funds reported $4.75M of Gain Therapeutics stock for Q1 2022, down 17% quarter-over-quarter.
- 1 fund opened new Gain Therapeutics positions in Q1 2022 and 4 closed out, a net change of -3 holders.
- The largest Gain Therapeutics buyer in Q1 2022 was Telemetry Investments, an estimated $372K added.
- The largest Gain Therapeutics seller in Q1 2022 was Two Sigma Investments, an estimated $106K sold.
Based on aggregated 13F filings for Q1 2022.